Drug makers & biotechDrug and biotech companies, with their PACs and trade groups. Pharmacies and distributors are under Other health companies.Business › Health
PAC (qualified)Lobbyist/registrant PACCorporationNew York, New YorkActive
“Ready for Cures is dedicated to improving access to life-saving medicines and fostering a public policy environment that supports healthcare innovation.”
Pfizer Inc., the organization this committee is the political fund of, pfizer.com
Quoted from the committee's site, or its sponsor's or funder's where its own says nothing. Any side it takes is in its own words.
3 priorities from the site of Pfizer Inc., the organization this committee is the political fund of, in the order they are listed there. Every heading and the text under it is copied exactly, as one passage for each page it is from, and links to that place on the page; hover a source to see which passage it opens.
3 priorities · 7 quoted statements
Our public policy activities focus on helping to build a constructive discourse in the political and regulatory environment while supporting policies – and policymakers – who share in our purpose and position us to better deliver these same ideals.
Ready for Cures is dedicated to improving access to life-saving medicines and fostering a public policy environment that supports healthcare innovation.
Waning budgets for scientific research and outdated regulatory policies create challenges in providing people and communities the best healthcare possible.
With your help, we can show elected officials that it’s time to support science and remove the barriers that continue to stand between life-saving medications and the patients who need them the most.
Who it gives toWhich candidates and committees get its money?
Each part reads different filings, so counts and totals can differ.
Party support distribution$684.3K to 185 candidates
Direct PAC contributions and independent expenditures explicitly reported as support, by the party of the candidate they went to.
For candidates $684,250
Republican 52%Democratic 35%
Support by the party of the candidate
Party of the candidate
Candidates
Direct
Independent
Amount
Share
Republican
82
$356,000
$0
$356,000
52%
Democratic
75
$240,750
$0
$240,750
35%
Other or unresolved
28
$87,500
$0
$87,500
13%
Shown support
185
$684,250
$0
$684,250
100%
Contributions are reported money, not endorsements; a PAC giving to both parties is common.
Who this PAC gave to$1,228,550 in 612 payments
Every contribution on line 23 of the committee’s own Schedule B, which is the filing its summary totals are built from. That line covers federal candidates, party committees and other political committees alike, so a super PAC funding other super PACs appears here rather than under candidate giving.
By recipient
Line 23 contributions by kind and party of recipient
Recipient
Count
Amount
Democratic candidates
76
$241.8K · 19%
Republican candidates
81
$355K · 28%
Other or unresolved candidates
29
$88.5K · 7%
Democratic party committees
3
$13.5K · 1.1%
Republican party committees
3
$19.2K · 1.5%
Other party committees
6
$167.5K · 13%
Other PACs and committees
80
$385.5K · 30%
All recipients
278
$1.3M
By the candidate’s state
Contributions to candidates by the candidate’s state
State
Candidates
Amount
California
19
$75.5K
North Carolina
11
$50.5K
New York
15
$48.3K
Florida
12
$42K
Pennsylvania
9
$38K
Texas
9
Show candidate activity and the money network
Candidate and election activity as the recipients filed it
Money inWho funds the PAC?
Where the money came from $1,472,098 reported receipts
Tap a row with to see who gave.
Itemized (over $200)Donors who have given more than $200 this cycle, so the FEC itemizes (names) them.$812,67355%
Largest donors
Ronald Blaylock7 contributions, latest Sep 25, 2026 · BOARD OF DIRECTORS · PFIZER INC · NEW YORK, NY$8,750
Shantanu Narayen7 contributions, latest Sep 25, 2026 · BOARD OF DIRECTORS · PFIZER INC · NEW YORK, NY$8,750
Cyrus Taraporevala7 contributions, latest Sep 25, 2026 · BOARD OF DIRECTORS · PFIZER INC · NEW YORK, NY$8,750
Albert Bourla40 contributions, latest Sep 30, 2026 · CHAIRMAN & CEO · PFIZER INC · NEW YORK, NY$8,320
Robert Ennis40 contributions, latest Sep 30, 2026 · VP & LEAD COMPL COUNSEL, US, LATAM, ON · PFIZER, INC · NEW YORK, NY$8,320
Timothy Hogan40 contributions, latest Sep 30, 2026 · SVP, GLOBAL POLICY & PUBLIC AFFAIRS · PFIZER, INC · NEW YORK, NY$8,320
Michael P. McDermott40 contributions, latest Sep 30, 2026 · CHIEF GLOBAL SUPPLY AND QUALITY OFFICE · PFIZER, INC. · NEW YORK, NY$8,320
Myron K. Terry40 contributions, latest Sep 30, 2026 · SENIOR DIRECTOR, POLITICAL OUTREACH · PFIZER INC · NEW YORK, NY$8,320
Jerome Mychalowych38 contributions, latest Sep 30, 2026 · SVP, GLOBAL TAX · PFIZER, INC · NEW YORK, NY$7,904
Melissa L. Bishop-Murphy37 contributions, latest Sep 30, 2026 · SENIOR DIRECTOR, SPGR SENIOR ADVISOR · PFIZER INC · NEW YORK, NY$7,696
David Denton37 contributions, latest Aug 14, 2026 · CHIEF FINANCIAL OFFICER, EXECUTIVE VIC · PFIZER INC. · NEW YORK, NY$7,696
Mortimer J. Buckley6 contributions, latest Sep 25, 2026 · BOARD OF DIRECTORS · PFIZER INC · NEW YORK, NY$7,500
A donor who gave several times appears once. The 12 largest donors by total given are listed. In all, 17,734 itemized contributions were filed this cycle, totaling $806.5K. FEC contributor lists are public records and cannot be used for commercial solicitation.
Unitemized ($200 or less)Donors who have given $200 or less this cycle, so the FEC does not itemize (name) them.$644,94644%
Refunds and rebatesMoney coming back to the committee: rebates and refunds of what it spent, contributions it made that were returned, and loans it made that were repaid.$13,5000.9%
Other receiptsInterest, dividends and other income the committee files on a line of its own.$980<0.1%
Where it came from
Audit Adjustment1 receipt, latest Jun 27, 2025 · New York, New York$980
Each as the committee named it on this line.
Total reported receipts $1,472,098
Every dollar the committee reported receiving this cycle, split by the source the FEC filing attributes it to. FEC filings through Oct 14, 2026.
Where the money traces to $1.5M followed back through up to 3 committees
19% to named individuals, 81% not itemized.
Gave directly$1.3M 89%
Gave directly
Name
Amount
Not itemized by this committee81%
$1,190,748
Ronald BlaylockPerson · Board of Directors, Pfizer Inc · New York, NY · 0.6%
$8,750
Shantanu NarayenPerson · Board of Directors, Pfizer Inc · New York, NY · 0.6%
$8,750
Cyrus TaraporevalaPerson · Board of Directors, Pfizer Inc · New York, NY · 0.6%
$8,750
Albert BourlaPerson · Chairman & CEO, Pfizer Inc · New York, NY · 0.6%
$8,320
Robert EnnisPerson · VP & Lead Compl Counsel, US, Latam, on, Pfizer, Inc · New York, NY · 0.6%
$8,320
Timothy HoganPerson · SVP, Global Policy & Public Affairs, Pfizer, Inc · New York, NY · 0.6%
Who donated: where they live, their employers and jobs
Where the donors live $806,545 placed by state
Loading the map
Tap or hover over a state, or focus the map and use the arrow keys, to read its total. Ctrl or ⌘ and scroll to zoom.
under $30.6K
$30.6K+
$122.6K+
$275.8K+
$490.4K+
none
Top states
Top donor states
Name
Amount
New York16,556 contributions · 95%
$766,210
New Jersey123 contributions · 0.5%
$4,316
Connecticut80 contributions · 0.4%
SpendingWhere does the money go?
How the spending splits $1,601,885 reported
Tap a row with to see who was paid.
Contributions to candidates and other committeesMoney given to federal candidates, party committees and other PACs.$1,242,05078%
Paid to
NRSC8 payments · latest Aug 19, 2026 · CONTRIBUTION$60,000
DSCC8 payments · latest Oct 13, 2026 · CONTRIBUTION$39,000
DCCC4 payments · latest Feb 2, 2026 · CONTRIBUTION$35,000
NRCC2 payments · latest Feb 2, 2026 · CONTRIBUTION$30,000
M-PAC3 payments · latest Aug 19, 2026 · CONTRIBUTION$10,000
Common Ground PAC3 payments · latest Oct 13, 2026 · CONTRIBUTION$10,000
NO Nonsense PAC2 payments · latest Jun 16, 2026 · CONTRIBUTION$10,000
Common Values PAC2 payments · latest Jun 16, 2026 · CONTRIBUTION$10,000
Other disbursementsEverything the committee reports outside the lines above.$359,20022%
Paid to
Operating expendituresThe committee's own running costs.$635<0.1%
Paid to
Internal Revenue Service1 payment · latest Oct 17, 2025 · FEDERAL TAX PAYMENT$450
Total reported disbursements $1,601,885
Every dollar this committee reported spending this cycle, split by the lines it reports against. Open a line to see who was actually paid on it. FEC filings through Oct 14, 2026.
What the payments were for $1,588,200 itemized
Tap a row with to see what was paid for.
Given to othersContributions to other candidates, party committees, and PACs.$1,712,65099.9%
Filed as
CONTRIBUTION$1,228,550
NONFEDERAL CONTRIBUTION$484,250
CONTRIBUTION TO NON-AFFILIATED COMMITTEE$12,000
CONTRIBUTION TO NON-AFFILIATED PAC$5,000
UNCASHED 6/23/25 CONTRIBUTION-$500
UNCASHED 7/15/25 CONTRIBUTION-$500
UNCASHED 8/27/25 CONTRIBUTION-$500
UNCASHED 11/6/25 CONTRIBUTION-$1,000
UNCASHED 9/17/25 CONTRIBUTION-$1,500
UNCASHED 12/15/25 CONTRIBUTION-$1,800
UNCASHED 4/30/25 CONTRIBUTION-$5,500
UNCASHED 9/23/25 CONTRIBUTION-$5,850
Paid to
Pfizer Missouri PAC - Federal Committee$31,000
DSCC$30,000
DCCC$30,000
NRCC$30,000
NRSC$30,000
NRSC$30,000
Taxes, fees, and bank charges
Spending over time
$1.6M spent from Jan 2025 to Oct 2026. Most in one report: $175K, February 2026.
$1.6M
Jan 2025Oct 2026
The running total of what the committee’s FEC reports say it spent, independent expenditures included, with a point at the end of each report. The line is straight between reports because a report gives one total for its whole period.
Each report’s total
Oct 1 – Oct 14, 2026$87,800
September 2026$35,350
August 2026$115,450
July 2026$105,350
June 2026$90,000
May 2026$109,500
April 2026$60,500
March 2026$89,750
February 2026$175,035
January 2026$2,650
December 2025$67,900
November 2025$25,050
October 2025$9,700
September 2025$129,125
August 2025$22,600
July 2025$61,325
June 2025$73,050
May 2025$78,500
April 2025$85,000
March 2025$80,500
February 2025$83,000
January 2025$14,750
Show other payments: transfers, refunds and the rest
Besides giving through its PAC, Pfizer, Inc. pays lobbyists to press Congress and federal agencies. Each quarter it, or a firm it hires, files a public report under the Lobbying Disclosure Act saying which topics it worked on, what it spent, and whom it contacted. This is what those reports say.
Spent on lobbying in 2026
$14.3M
Quarterly reports read
38
Bills it named
23
Topics it lobbied on
Each report files its work under official topics. The bar shows how often each topic came up across the reports; open one to read what was filed under it. Naming a bill says the organization lobbied on it, not which side it took.
Health Issuesin 23 report entries · 12 bills named
In its own words
Vaccine Coverage and Coverage Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Codification and Sec. 301 trade investigations FDA User Fee Agreements: 2027 PDUFA Cycle H.R. 7837 - Most Favored Patient Act of 2026 H.R. 7391 - Community Health Center Drug Pricing Protection Act 340B Program Reform Inflation Reduction Act (IRA) H.R. 8646 - Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriates Act, 2027 H.R. 9260 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriation Act, 2027 H.R. 5178 - Sickle Cell Disease Comprehensive Care Act H.R. 5526 - Biosimilars Red Tape Elimination Act H.R. 4930 - To Expand the Sharing of Information with Respect to Suspected Violations of Intellectual Property Rights in Trade H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act: IRA reforms Prior Authorization Step Therapy Practices FDA Modernization and Reforms Drug Pricing PBM Reform Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage
H.R. 4101 - Cancer Drug Parity Act of 2025 H.R. 5178 - Sickle Cell Disease Comprehensive Care Act S. 3510 - Biosimilar Inspection Modernization Act of 2025 Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Codification FDA-2026-N-4699 - Expedited Investigational New Drug (IND) pilot program Section 301 Investigation re: Germany Issues FDA User Fee Agreements: 2027 PDUFA Cycle 340B Program Reform Prior Authorization Vaccine Access and Coverage FDA Modernization and Reforms Drug Pricing PBM Reform Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage Pandemic and All-Hazards Preparedness Act (PAHPA)
Vaccine Coverage Pediatric Immunization Schedule Vaccine Injury Compensation Program Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 7837 - Most Favored Patient Act of 2026 Lyme Disease Issues 340B Issues Counterfeit Drugs Inflation Reduction Act (IRA) Prescription Drug User Fee Act (PDUFA) Drug Pricing PBM Reform Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage H.R. 5509 - Safe Step Act S. 2903 - Safe Step Act S. 3510 - Biosimilar Inspection Modernization Act of 2025
General education about policies impacting pharmaceutical development, approval and reimbursement;
Drug safety and drug counterfeiting; drug importation; and drug shortages.
Drug pricing proposals.
The 340B program.
Pharmacy benefit manager reform proposals, issues related to headache and migraine.
P.L. 119-21.
Legislation and issues related to prior authorization.
Issues related to TrumpRX.
Issues related to drug development and pricing, generally vaccine safety and access, generally the 340B program, Issues related to pharmacy benefit managers, generally. H.R. 5509, the Safe Step Act
Medicare/Medicaidin 14 report entries · 4 bills named
In its own words
H.R. 7391 - Community Health Center Drug Pricing Protection Act Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Vaccine Access and Coverage 340B Program Reform PBM Reform Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage Step Therapy Practices Drug Pricing Medicare/Medicaid Issues
Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Prescription Drug User Fee Act (PDUFA) 340B Issues Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage PBM Reform Counterfeit Drugs P.L. 117-169 - Inflation Reduction Act (IRA) of 2022 Drug Pricing Medicare/Medicaid Issues
H.R. 5256 - 340B ACCESS Act H.R. 9599 - SECURE 340B Act Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Vaccine Access and Coverage 340B Program Reform Hospital Outpatient Prospective Payment System (OPPS) Proposed Rule/Essential Medicines PBM Reform Drug Pricing Medicare/Medicaid Issues
Medicare payment issues and Medicaid issues.
Medicare Part D. Drug pricing proposals.
Protecting Seniors Through Immunization Act.
Pharmacy benefit manager reform proposals.
H.R. 1, "One Big Beautiful Bill Act", issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN.
Taxation/Internal Revenue Codein 13 report entries · 2 bills named
In its own words
Issues related to corporate and international taxation.
Issues related to OECD Pillar 1 and Pillar 2 negotiations, agreements, implementation, and reporting related to the taxation of global income.
Issues related to IRC sections 11, 163(j), 951A, and 250.
Issues related to OECD Pillar 1 and Pillar 2 negotiations and agreements on the taxation of global income.
Issues related to IRC sections 11, 951A, 250, 163(j), and 174.
Tax issues affecting the pharmaceutical industry including international tax; implementation of PL 119-21. Vaccine excise tax issues and VICP.
H.R. 1 - An Act to Provide for Reconciliation Pursuant to Title II of H. Con. Res. 14
Issues related to vaccine excise taxes and the Vaccine Injury Compensation Fund.
General issues with tax reform and foreign tax issues.
Trade (domestic/foreign)in 13 report entries · 2 bills named
In its own words
H.R. 9102 - Biotech Investment National Security Act (BINSA) Act: US Competitiveness, Biotechnology Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients FDA-2026-N-4699 - Expedited Investigational New Drug (IND) pilot program International Supply Chain Section 301 Investigation re: Germany Issues Foreign Freeriding Issues Non-Tariff Trade Barriers Global Health Competitiveness Issues Clinical Trial Issues
H.R. 9102 - Biotech Investment National Security Act (BINSA) Act: US Competitiveness, Biotechnology H.R. 4930 - To Expand the Sharing of Information with Respect to Suspected Violations of Intellectual Property Rights in Trade International Supply Chain Section 301 Investigation re: Germany Issues Market Access Most Favored Nation Policies Foreign Freeriding Issues Non-Tariff Trade Barriers Competitiveness Issues Trade Issues
Issues related to pharmaceutical manufacturing and development, trade and tariffs; potential tariff actions under Section 232 of the Trade Act of 1962. Issues related to China WRT the BINSA Bill.
International Supply Chain Market Access Most Favored Nation Policies Foreign Freeriding Issues Non-Tariff Trade Barriers Competiveness Issues Trade Issues
Issues related to pharmaceutical manufacturing and development, trade and tariffs; potential tariff actions under Section 232 of the Trade Act of 1962.
Copyright/Patent/Trademarkin 6 report entries · 3 bills named
In its own words
Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.
Intellectual Property Protections and Policy S. 2658 - Medication Affordability and Patent Integrity Act
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients.
H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Issues related to vaccine development, distribution and injury compensation.
Issues related to FDA regulation of pharmaceuticals.
Issues related to prescription drug pricing and pharmacy benefit manager business practices, including Division J of H.R.7148 - Consolidated Appropriations Act, 2026, PL 119-75.
Issues related to the 340B program.
H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program Issues related to vaccine development, distribution and injury compensation.
Issues related to prescription drug pricing and pharmacy benefit manager business practices.
Drug pricing and Medicare, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients.
Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act;
Budget/Appropriationsin 5 report entries
In its own words
Policies impacting post pandemic public health emergency Covid-19 vaccine reimbursement and distribution.
Support for immunization access, access to migraine screening.
Support for tick-borne disease research and womens health.
Support for immunization access, access to migraine screening. Support for tick-borne disease research and womens health.
Issues related to FY27 health appropriations
Offices it contacted
HOUSE OF REPRESENTATIVES
SENATE
Defensein 3 report entries
In its own words
Issues related to pharmaceutical manufacturing and development. Issues related to China WRT the BINSA bill.
Issues related to pharmaceutical manufacturing and development.
Offices it contacted
HOUSE OF REPRESENTATIVES
SENATE
Who did the lobbying
The organization’s own reports give its total lobbying costs, including any firms it hired; each firm reports what this client paid it.
Pfizer Inc.Its own staff · 4 reports$14.3M
Miller Strategies, LLCLobbying firm · 3 reports$450K
BGR Government AffairsLobbying firm · 4 reports$180K
Federal Health Policy StrategiesLobbying firm · 3 reports$180K
Reported twice a year by the lobbying filer. $68.5K is political giving that also appears in FEC filings.
Various Republican Senatorial Candidates$13.8K
U.S. Senator John Cornyn$6.8K
U.S. Senator Ashley Moody$6K
Various Republican Congressional Candidates$6K
U.S. Representative Brett Guthrie$5K
U.S. Representative Andy Barr, Candidate for U.S. Senate$3.5K
U.S. Representative Ashley Hinson, Candidate for U.S. Senate$3.5K
U.S. Senator Eric Schmitt$3K
U.S. Senator Katie Britt$3K
U.S. Senator John Barrasso$2.5K
Matched by name: these reports are filed for “PFIZER, INC.”, found by searching “PFIZER”. Lobbying and FEC records share no ID, so an organization that lobbies under another name is missed. Source: LDA.gov, accessed Nov 8, 2026. Senate Office of Public Records cannot vouch for the data or analyses derived from these data after the data have been retrieved from LDA.gov.
Pfizer Inc. PAC is registered with the Federal Election Commission as a PAC (qualified). It is a lobbyist/registrant PAC. Its FEC record names Pfizer Inc. as an affiliate. Official FEC summary: Federal Election Commission committee record.
Bars drawn to $60K, the largest gift total here. 2025–2026 filings.
Nicole Malliotakis4 receipts, latest May 20, 2026Nicole for New York · H0NY11078$10K
Ben Ray Lujan2 receipts, latest Feb 17, 2026People for Ben · S0NM00058$10K
John Cornyn4 receipts, latest Mar 19, 2026Texans for Senator John Cornyn Inc. · S2TX00106$10K
Nanette Barragan6 receipts, latest Feb 17, 2026Barragan for Congress · H6CA44103$10K
Richard W. Allen3 receipts, latest Feb 17, 2026Rick W. Allen for Congress · H2GA12121$10K
Candidate contribution rows come from candidate committee Schedule A filings, the same rows the party chart above counts.
Committee money network
Money moving between this committee and other committees, matched on FEC committee ID rather than the name each filing was typed under. Both sides exclude memo entries. The figures here count each committee once, from the itemized transfers read for this section, so they will not match the payment counts under Who this PAC gave to.
Committees funding this one
Committees that reported giving to this one on their own Schedule A filings, grouped by the giver’s committee ID.
No committee-to-committee receipts were itemized this cycle.
Committees this one funds
Disbursements this committee itemized to another committee: candidate contributions, party transfers and payments alike, not contributions only.
Committees this one funds
Name
Amount
NRSCParty committee (qualified) · Connected to YOUNG VICTORY COMMITTEE · 8 payments
NO Nonsense PACPAC (qualified) · Connected to MALLIOTAKIS VICTORY COMMITTEE · 2 payments
$10K
Common Values PACPAC (qualified) · Connected to BARRASSO · 2 payments
$10K
$1.3M across 294 recipient committees, or 79% of everything this committee reports spending. The largest 12 are shown. A further $6.5K was filed as memo entries, which FEC reports separately to avoid counting it twice.
Built from FEC Schedule A and Schedule B filings for the selected cycle. A committee only appears here if the money was itemized under its FEC committee ID.
$8,320
Michael P. McDermottPerson · Chief Global Supply and Quality Office, Pfizer, Inc. · New York, NY · 0.6%
$8,320
Myron K. TerryPerson · Senior Director, Political Outreach, Pfizer Inc · New York, NY · 0.6%
$8,320
Jerome MychalowychPerson · SVP, Global Tax, Pfizer, Inc · New York, NY · 0.5%
$7,904
Show 5 more sources
Gave directly, more
Name
Amount
Melissa L. Bishop-MurphyPerson · Senior Director, SPGR Senior Advisor, Pfizer Inc · New York, NY · 0.5%
$7,696
David DentonPerson · Chief Financial Officer, Executive Vic, Pfizer Inc. · New York, NY · 0.5%
$7,696
Mortimer J. BuckleyPerson · Board of Directors, Pfizer Inc · New York, NY · 0.5%
$7,500
Suzanne Nora JohnsonPerson · Board of Directors, Pfizer Inc · New York, NY · 0.5%
$7,500
James C. SmithPerson · Board of Directors, Pfizer Inc · New York, NY · 0.5%
$7,500
37 smaller sources, $167.7K in all (11%), are not listed.
Each committee that gave is followed to where its own money came from, in proportion to what it received: a committee that got half its money from one person is counted as passing half of what it gave on to that person. Each channel shows the committee the money came through and its place in the money tree. It shows who stood behind the money, not what that money was for, and an organization that need not name its donors ends the trail. It stops at a person, an organization, a committee with nothing on file here, or 3committees deep. A person who gave by more than one route appears under each, a name filed two ways may appear twice, and a person's job and city are as they filed them. "Also behind" counts the other groups, among those that moved $100,000 or more into races, in which $100,000 or more traces to the same person, other than those this money came through or went on to.
$3,504
Florida74 contributions · 0.4%
$2,917
Pennsylvania110 contributions · 0.4%
$2,825
North Carolina67 contributions · 0.3%
$2,699
California57 contributions · 0.3%
$2,057
Maryland38 contributions · 0.2%
$2,016
By the state each contributor wrote on the filing. The FEC aggregates every Schedule A line together, so one committee or organization transfer can account for a whole state. Contributors who have given $200 or less this cycle are not itemized and cannot be placed on a map. The FEC’s grouping also counts joint-fundraising memo lines, so these rows can add up to more than the itemized total.
Donors’ employers as filed
Donors’ employers
Employer as filed
Amount
Pfizer INC15,624 contributions · 92% of ranked
$742,671
Pharmacia & Upjohn Company988 contributions · 4% of ranked
$32,525
Pfizer Global Research And Developmen243 contributions · 1.2% of ranked
$9,298
Pfizer U S Pharmaceuticals279 contributions · 0.9% of ranked
$7,384
Pharmacia233 contributions · 0.6% of ranked
$4,980
Pfizer Pharmaceuticals LLC116 contributions · 0.5% of ranked
$4,102
Pfizer Global Manufacturing-us53 contributions · 0.2% of ranked
$1,734
Pfizer Legal-us75 contributions · 0.2% of ranked
$1,695
Itemized receipts grouped by the words contributors filed. The FEC aggregates every Schedule A line here, so committee and organization money sits alongside individuals; this is not an industry classification. The FEC’s grouping also counts joint-fundraising memo lines, so these rows can add up to more than the itemized total. Gifts of $200 or less ($644,946) are not itemized, so no employer or occupation is filed for them.
Donors’ occupations as filed
Donors’ occupations
Occupation as filed
Amount
Board Of Directors36 contributions · 6.6% of ranked
$45,000
Area Business Manager1,178 contributions · 4.7% of ranked
$31,610
Director State Government Relations264 contributions · 4.2% of ranked
$28,726
SHR Level 4595 contributions · 2.8% of ranked
$18,666
SHR Level 3706 contributions · 2.4% of ranked
$16,035
SHR Level 2463 contributions · 2.3% of ranked
$15,263
HSP Level 3566 contributions · 2% of ranked
$13,759
Senior Director Federal Government RE116 contributions · 1.9% of ranked
$12,956
Ranked from the largest 200 of 201 occupation spellings filed; each share is of the money in those. Itemized receipts grouped by the words contributors filed. The FEC aggregates every Schedule A line here, so committee and organization money sits alongside individuals; this is not an industry classification. The FEC’s grouping also counts joint-fundraising memo lines, so these rows can add up to more than the itemized total. Gifts of $200 or less ($644,946) are not itemized, so no employer or occupation is filed for them.
Pfizer Missouri PAC - Federal Committee4 payments · latest Oct 2, 2026 · NONFEDERAL CONTRIBUTION$31,000
Republican State Leadership Committee5 payments · latest Jun 16, 2026 · NONFEDERAL CONTRIBUTION$12,000
Payroll and income taxes, filing fees, bank and merchant processing charges.
$450<0.1%
Filed as
FEDERAL TAX PAYMENT$450
Paid to
Internal Revenue Service$450
Total itemized disbursements $1,588,200
Every itemized payment the committee reported this cycle, sorted by what it said each one was for. The categories are ours; the wording they are matched against is the committee’s own. Open a category to read the filed descriptions and who was paid. FEC filings through Oct 14, 2026.
All 1,415 itemized payments filed this cycle. Spending below the itemization threshold is not filed line by line.
The people, firms and committees paid the most, across every kind of payment. Each share is of everything the committee reported spending this cycle, not only the itemized payments above. A payee that is itself a committee links to its own profile.
Pfizer Missouri PAC - Federal Committee4 payments, latest Oct 2, 2026NONFEDERAL CONTRIBUTION$31K
Republican State Leadership Committee5 payments, latest Jun 16, 2026NONFEDERAL CONTRIBUTION$12K
Shapiro for PA1 payment, latest Jul 14, 2026NONFEDERAL CONTRIBUTION$10K
Masterson for Governor2 payments, latest Oct 2, 2026NONFEDERAL CONTRIBUTION$8K
CAM PAC2 payments, latest Aug 19, 2026NONFEDERAL CONTRIBUTION$7.5K
Transfers, refunds, and everything else the committee itemized outside candidate giving. 802 payments totaling $359.2K.
P.L. 119-21.
Issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN.
Direct-to-Patient Prescription Drug Purchase Platforms Most Favored Nation drug pricing 340B HHS Pilot Program Model